Policy Advocacy & Reform

The American Academy of Child and Adolescent Psychiatry (AACAP) is a major US professional medical association representing child and adolescent psychiatrists and publisher of the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP). The organization and its journal have actively engaged with questions around psychedelic-assisted therapy for youth, publishing clinical research and ethical analyses on the potential use of psilocybin and MDMA in adolescent populations.

US professional psychiatric body that publishes position statements and guidance relevant to evidence standards and clinical policy considerations for psychedelic and empathogenic therapies.

The Association for Psychedelic Science and Therapy Austria connects mental health professionals and improves public awareness of safe, ethical, evidence-based psychedelic therapies.

Founded in 2020, the Autistic Psychedelic Community (APC) is a Los Angeles-based peer support and co-learning network focused on the intersection of psychedelics and neurodivergent conditions including autism and ADHD, offering psychedelic integration support, panel discussions with researchers, and academic partnerships. Cited in peer-reviewed research, the APC promotes neurodiversity-affirming approaches to psychedelic practice and safe access.

Longstanding non-profit foundation supporting and convening psychedelic and drug-policy research programs.

Policy-focused organization producing legislative analysis and implementation guidance on affordable, state-regulated psychedelic care pathways.

The Centre for Evidence Based Drug Policy is a UK think tank promoting evidence-based drug policy to reduce harm, improve public health, and unlock medical and economic benefits.

Cepda is a Danish non-profit think tank working on psychedelic education, community building, advocacy, and research collaboration among professionals, researchers, and people with lived experience.

Nonprofit platform focused on psychedelic education, cultural justice, and Indigenous reciprocity with programming at the intersection of ethics, policy, and community knowledge.

Washington state coalition advocating supervised psilocybin access legislation and coalition-based policy campaigns for veterans, first responders, and affected communities.

Statutorily created Colorado advisory board providing implementation recommendations for natural medicine regulation, safety standards, licensing architecture, and program oversight priorities.

Bipartisan U.S. congressional caucus focused on advancing evidence-informed psychedelic policy pathways, with a recurring emphasis on veterans mental health and federal research support.

Grassroots campaign network focused on decriminalizing entheogenic plants and fungi through local policy campaigns, public education, and community organizing.

US nonprofit policy advocacy organization working to end the war on drugs through legislation, research translation, and public education, including reforms related to psychedelic policy and decriminalization.

Drug Science is a UK-based independent scientific body that supports evidence-led drug policy and public education, and has played a visible role in psychedelic research translation, communication, and policy discourse.

The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.

The European Federation of Neurological Associations (EFNA) is a Brussels-based umbrella organization representing 21 pan-European neurology patient groups, advocating for improved access and resources for people with neurological disorders. EFNA participates as a patient advocacy partner in the PsyPal consortium, the first EU-funded multi-site psilocybin clinical trial (€6.5M) studying psilocybin for psychological distress in palliative care neurological patients.

Fundación inawe is a Spanish non-profit promoting mental health innovation by developing an ecosystem for implementing psychedelic-assisted therapies in Spain.

The German Society for Psychedelic Research and Therapy is a professional association for physicians, psychologists, and other professionals supporting scientific work and potential clinical introduction of psychedelic therapies.

HYSTELICA is a non-profit researching, advocating, and educating for safe and effective psychedelic use for women, with a focus on ensuring women-specific needs shape the future of psychedelics.

Heal Ukraine Trauma is a U.S.-based non-profit providing evidence-based mental health support to Ukrainian veterans and their families healing from war trauma.

Nonprofit campaign and implementation-support organization focused on expanding and protecting safe, affordable, state-regulated psychedelic therapy access, including Oregon and Colorado programs.

Veteran-serving nonprofit supporting access to psychedelic programs and advocating policy pathways that expand safe treatment options for veterans and their families.

Heroic Hearts UK connects UK military and emergency services veterans with psychedelic therapy retreat centres in countries where those practices are legal.

HoloMind is a Polish initiative educating the public about therapeutic psychedelic use and advocating for psychedelic treatments in Poland.

Nonprofit organization supporting evidence, policy, and community-centered programs around psychedelic plants, including Indigenous reciprocity and traditional knowledge initiatives.

IHPI (Ibogaine Healthcare Policy Institute) is a 501(c)(3) nonprofit building policy infrastructure for regulated ibogaine care in the United States. Its work focuses on decision-grade resources for healthcare leaders, including safety and delivery standards, regulatory pathways, reimbursement mechanics, payment/coding roadmaps, coverage criteria, and implementation planning. The organization was founded on 1 January 2026 and is incubated by Delphi.

Icelandic Psychedelic Society - Hugvikkandi is a platform for people interested in psychedelics to build community, strengthen advocacy, educate themselves, support research and legal progress, and collaborate internationally.

Independent multidisciplinary working group assessing evidence-evaluation frameworks for psychedelic therapies to inform regulators and policy design.

The International Alliance of MDMA Practitioners (MDMA Alliance) is a professional network focused on standards, training, and shared learning for MDMA-assisted therapy practitioners and allied clinicians.

Irish Doctors for Psychedelic Assisted Therapy is a non-profit improving awareness of psychedelic research among clinicians and policymakers and advocating for state-funded psychedelic research trials.

SIMEPSI is an Italian multidisciplinary non-profit promoting psychedelic research, cultural awareness, regulatory frameworks for safe treatments, knowledge exchange, and public education.

Kykeon works to destigmatize psychedelics in Greece through community building, education, interdisciplinary dialogue on therapeutic use, and drug policy reform advocacy.

Luca Coscioni Association works with experts, researchers, and scientists to prepare technical documents supporting legislative, judiciary, and policy proposals and amendments.

Long Alliantie Nederland (Lung Alliance Netherlands) is the Dutch national patient alliance representing people with lung diseases including COPD, asthma, and pulmonary fibrosis; as one of 19 consortium partners in the EU Horizon Europe–funded PsyPal trial (€6.5M), the Alliance contributes patient expertise for the COPD arm investigating psilocybin therapy for psychological distress in palliative care.

Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.

The Amsterdam-based European subsidiary of MAPS (Multidisciplinary Association for Psychedelic Studies), MAPS Europe B.V. was established in 2018 to advance MDMA-assisted psychotherapy through EMA-regulated Phase 2 and Phase 3 clinical trials for PTSD across Europe. The organization ran the first multi-site European MDMA/PTSD Phase 2 open-label study with sites in London, Berlin, Lisbon, and others, and trained therapists from 14 countries.

MAPS Italia is a non-profit founded in 2024 to support informed dialogue, education, research, and advocacy for therapeutic uses of psychedelic substances in Italy.

Australian registered charity founded in 2019 that successfully campaigned for the Therapeutic Goods Administration (TGA) to reschedule psilocybin and MDMA in 2023 — making Australia the first country to formally approve these substances for clinical use. MMA trains clinicians through its Certificate in Psychedelic-Assisted Therapies (CPAT) program, funds clinical trials, and has supplied medicines and training to 100+ patients under the TGA Authorised Prescriber scheme.

The National Association for Psychedelic Research in Serbia promotes education, dialogue, and research advocacy around psychedelics in mental health, translating scientific findings for professionals and the public.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

State advisory board charged with issuing recommendations to Oregon Health Authority on psilocybin services implementation, professional standards, public health safeguards, and operational controls.

The Polish Psychedelic Society popularizes and supports scientific research on psychedelic substances and provides space for debate about their application in science, medicine, psychotherapy, and culture.

Psilocybin Access Rights is a volunteer campaign pressing the UK government to reschedule psilocybin and make it accessible for patients and researchers.

EU-wide European Citizens’ Initiative campaigning for standardized psychedelic therapy guidelines, expanded EU research funding, and aligned international legal classification policy.

European multi-stakeholder alliance coordinating advocacy, policy dialogue, and member working groups to improve access, reimbursement, and responsible integration of psychedelic therapies.

Psychedelic Coalition for Health (PCH) is a clinician-led psychedelic medicine education and advocacy organization co-founded by psychotherapists Lauren Taus and Nicholas Brüss, offering psychedelic-assisted therapy training, virtual symposia, and scholarship programs for healthcare professionals. PCH trains licensed clinicians in ketamine, MDMA, and IFS-informed approaches while advocating for equitable access to and responsible implementation of psychedelic medicine.

Washington, D.C.-based nonprofit advocacy organization focused on federal and state psychedelic policy, lawmaker education, and coalition-building for safe and equitable access.

US political action organization supporting candidates and policy movements that advance evidence-based psychedelic medicine access and rescheduling at state and federal levels.

PRISM is an Australian nonprofit organization advancing evidence-based psychedelic science, policy, and public education through research communication, expert engagement, and policy-facing advocacy.

Belgium-based nonprofit community organization advancing psychedelic public education, events, and informed dialogue through outreach activities.

European advocacy platform convening policymakers, regulators, researchers, and businesses to develop EU regulatory pathways for psychedelic therapies.

Reconnect Foundation is a Swiss non-profit supporting consciousness research, mental health care accessibility, and Indigenous stewardship of ecosystems and biodiversity.

UK drugs policy and legal reform organization advancing rights-based drug policy change, including evidence-led approaches relevant to psychedelic policy and access.

Salt City Psychedelic Therapy and Research (SCPTR) is a Utah-based nonprofit founded by the late Dr. Parth Gandhi to advance psychedelic-assisted therapy through education, research, and advocacy in the Intermountain West. SCPTR organizes the annual Intermountain Psychedelic Symposium and supports practitioners, researchers, and policy reform in the region.

SPACE is a Portuguese scientific association founded in 2021 by psychiatry doctors to study, disseminate, and promote knowledge about the potential therapeutic uses of psychedelic substances.

The Société Psychédélique Française is a French hub for young researchers, students, scientific and cultural mediation, and community discussion grounded in responsibility and harm reduction.

SEMPsi brings together medical doctors, psychologists, and mental health researchers to promote evidence-based psychedelic therapy and research in an ethical, scientific, and culturally respectful context.

Global youth-led network advocating evidence-based drug policy reform through campus organizing, policy campaigns, and public education that include psychedelic reform issues.

The Swiss Medical Association for Psychedelic Therapy (SÄPT) is a Switzerland-based professional medical association focused on clinical standards, practitioner community building, and responsible development of psychedelic-assisted therapy.

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

UK-based policy foundation supporting evidence-driven drug policy reform, including psychedelic policy pathways.

The Ukrainian Psychedelic Research Association convenes academics, clinicians, patients, and activists to advance legal therapeutic use and scientific psychedelic research in Ukraine.

Veteran-led nonprofit coalition advocating federal and state policy reform to expand access to psychedelic-assisted therapies and reduce veteran suicide.

Veteran-focused nonprofit advocating expanded access to psychedelic-assisted therapies, especially for PTSD and related conditions, through policy engagement and public education.